preclinical research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-20. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
=== COVID 19 === The COVID 19 pandemic marked a new chapter in Hetero’s public health contributions. In March 2020, as the pandemic took hold, Hetero donated INR 10 crore to the Telangana government’s COVID relief fund, composed of 5 crores in direct funding and 5 crores in essential medicines including Hydroxychloroquine Sulphate, Lopinavir/Ritonavir and Oseltamivir. During this period, Hetero also began supplying medicines to countries such as the United States, Italy, Spain, Israel, and Algeria. In May 2020, Hetero entered a licensing agreement with Gilead Sciences to manufacture and distribute a generic version of Remdesivir in 127 countries. The Drug Controller General of India granted manufacturing and marketing approval on 21 June 2020, making Covifor the first generic Remdesivir approved in India. An initial consignment of 20000 Vials was distributed within India across major cities including Hyderabad, Delhi, Mumbai, Kolkata and Chennai, priced at ₹5400 per vial. By August 2020, Hetero had supplied approximately 800000 doses of Remdesivir in India alone, treating more than 100000 patients. In the same month, Hetero received authorization from the South African Health Products Regulatory Authority (SAHPRA) to import 'Remdesivir' in South Africa for the treatment for Covid-19, and committed to supplying 60000 vials a month. In July 2020, Hetero received approval from the DCGI to manufacture and market a generic version of Favipiravir tablets under the name Favivir, which is used to treat patients with mild to moderate COVID-19 symptoms.
== Pathogenesis == In susceptible persons, beryllium exposure can lead to a cell-mediated immune response. The T-cells become sensitized to beryllium. Each subsequent exposure leads to an immune response involving CD4+ helper T-lymphocytes and macrophages accumulating in the lungs. As this response continues macrophages, CD4+ T-lymphocytes and plasma cells aggregate together to form the noncaseating granulomas. When beryllium is phagocytized by macrophages, the beryllium triggers macrophage apoptosis, thereby reducing beryllium clearance from the lungs and eventually resulting in secondary necrosis and lysis. Eventually, the outcome is fibrosis of the lung. Several studies have shown that there is a genetic component to beryllium sensitivity. Specifically, those beryllium-exposed workers with a mutation at the HLA-DPB1 Glu69 position have increased prevalence of beryllium sensitization and chronic beryllium disease. The HLA-DPB1 gene is important for MHC class II molecule function on antigen presenting cells. A study of the immune response to beryllium in individuals who express the HLA-DP2 allele found that CD4 T-cells do not detect the Be2+ cation itself, but instead detect surface changes in the HLA-DP2/peptide complex in which Be2+ is embedded. Those researchers concluded that chronic beryllium disease is a predisposition that lies between "allergic hypersensitivity and autoimmunity." According to the International Agency for Research on Cancer, beryllium and beryllium compounds are Category 1 carcinogens; they are carcinogenic to both animals and humans.
Although hot dogs are cooked during manufacture, it is still recommended that packaged hot dogs be heated to an internal temperature of at least 165 °F (75 °C) before consumption. Hot dogs are a form of processed meat. According to the International Agency for Research on Cancer (IARC), processed meat causes cancer, particularly colorectal cancer. Most hot dogs contain nitrite and/or nitrate preservatives, which react with amines in meat to form carcinogenic N-nitroso compounds. Hot dogs are also high in fat and salt. An American Institute for Cancer Research (AICR) report found that consuming one daily 50-gram serving of processed meat—about one hot dog—increases long-term risk of colorectal cancer by 20%. Thus, eating a hot dog every day would increase the probability of developing colorectal cancer by 5.8–7%. The AICR's warning campaign has been criticized as being "attack ads" by conservative news organization Fox News. The Cancer Project group filed a class-action lawsuit demanding warning labels on packages and at sporting events. Due to their size, shape, and ubiquitous consumption, hot dogs present a significant choking risk, especially for children. A study in the US found that 17% of food-related asphyxiations among children younger than 10 years of age were caused by hot dogs. The risk of choking on a hot dog is greatly reduced by slicing it. It has been suggested that redesigning the size, shape, and texture of hot dogs would reduce the risk of choking.
Sources: en.wikipedia.org
Australia has adopted a number of strategies to combat money laundering, which mirror those of a majority of western countries. The Australian Transaction Reports and Analysis Centre (AUSTRAC) is Australia's financial intelligence unit to combat money laundering and terrorism financing, which requires every provider of designated services in Australia to report to it suspicious cash or other transactions and other specific information. The Attorney-General's Department maintains a list of outlawed terror organisations. It is an offense to materially support or be supported by such organisations. It is an offence to open a bank account in Australia in a false name, and rigorous procedures must be followed when new bank accounts are opened. The Anti–Money Laundering and Counter–Terrorism Financing Act 2006 (Cth) (AML/CTF Act) is the principal legislative instrument, although there are also offence provisions contained in Division 400 of the Criminal Code Act 1995 (Cth). Upon its introduction, it was intended that the AML/CTF Act would be further amended by a second tranche of reforms extending to designated non-financial businesses and professions (DNFBPs) including, inter alia, lawyers, accountants, jewellers and real estate agents; however, those further reforms have yet to be progressed. The Proceeds of Crime Act 2002 (Cth) imposes criminal penalties on a person who engages in money laundering.
== Further reading == DuBois, Page (1991). Centaurs and Amazons: Women and the Pre-History of the Great Chain of Being. University of Michigan Press. ISBN 0-472-08153-5. Ewans, Michael (2007). Opera from the Greek: Studies in the Poetics of Appropriation. Ashgate Publishing, Ltd. ISBN 978-0-7546-6099-6. ISBN 978-0-7546-6099-6 Gregory, Justina (2005). A Companion to Greek Tragedy. Wiley-Blackwell. ISBN 1-4051-0770-7. Griffiths, Emma (2006). Medea. Taylor & Francis. ISBN 0-415-30070-3. ISBN 978-0-415-30070-4 Hall, Edith (1991). Inventing the Barbarian: Greek Self-definition through Tragedy. Oxford University Press. ISBN 0-19-814780-5. Haralu, L. (2017). Madwomen and Mad Women: An Analysis of the Use of Female Insanity and Anger in Narrative Fiction, From Vilification to Validation. ProQuest Dissertations Publishing. (Accession No. 10643100) Lootens, Barbara J. "Images of Women in Greek Drama." Feminist Teacher, vol. 2, no. 1, 1986, pp. 24–28. JSTOR, JSTOR 25680553. Accessed 27 Mar. 2023. Mastronarde, Donald (2002). Euripides: Medea. Cambridge University Press. ISBN 0-521-64386-4. McDermott, Emily (1989). Euripides' Medea: the Incarnation of Disorder. Penn State Press. ISBN 0-271-00647-1. ISBN 978-0-271-00647-5 McDonald, Marianne (1997). "Medea as Politician and Diva: Riding the Dragon into the Future". In Ckauss, James; Johnston, Sarah Iles (eds.). Medea: Essays on Medea in Myth, Literature, Philosophy, and Art. Princeton University Press. ISBN 0-691-04376-0. Mitchell-Boyask, Robin (2008). Euripides: Medea. Translated by Diane Arnson Svarlien. Hackett Publishing.
This list of nuclides shows observed nuclides that either are stable or, if radioactive, have half-lives longer than one hour. This includes isotopes of the first 105 elements, except for 87 (francium), 102 (nobelium) and 104 (rutherfordium). More than 5,000 nuclides have been experimentally characterized, including isomers, of which this page presently includes 987.
Sources: en.wikipedia.org
=== Hormonal control === Lactiferous duct development occurs in females in response to circulating hormones. First development is frequently seen during pre- and postnatal stages, and later during puberty. Estrogen promotes branching differentiation, whereas in males testosterone inhibits it. A mature duct tree reaching the limit of the fat pad of the mammary gland comes into being by bifurcation of duct terminal end buds (TEB), secondary branches sprouting from primary ducts and proper duct lumen formation. These processes are tightly modulated by components of mammary epithelial ECM interacting with systemic hormones and local secreting factors. However, for each mechanism the epithelial cells' "niche" can be delicately unique with different membrane receptor profiles and basement membrane thickness from specific branching area to area, so as to regulate cell growth or differentiation sub-locally. Important players include beta-1 integrin, epidermal growth factor receptor (EGFR), laminin-1/5, collagen-IV, matrix metalloproteinase (MMPs), heparan sulfate proteoglycans, and others. Elevated circulating level of growth hormone and estrogen get to multipotent cap cells on TEB tips through a thin, leaky layer of basement membrane. These hormones promote specific gene expression. Hence cap cells can differentiate into myoepithelial and luminal (duct) epithelial cells, and the increased amount of activated MMPs can degrade surrounding ECM helping duct buds to reach further in the fat pads.
== Presentation == Patients usually begin to notice symptoms in their 30s and the course is usually slowly progressive. Common features include peripheral neuropathy, cardiomyopathy, and hemolytic anemia. Other features include limb chorea, facial tics, other oral movements (lip and tongue biting), seizures, a late-onset dementia, and behavioral changes.
=== Prohibition of tobacco === A few countries have outlawed tobacco completely or made plans to do so. In 2004, Bhutan became the first country in the world to completely outlaw the cultivation, harvesting, production, and sale of tobacco and tobacco products. Enforcement of the prohibition increased with the passage of the Tobacco Control Act of Bhutan 2010. However, small allowances for personal possession are permitted as long as the possessors can prove that they have paid import duties. The Pitcairn Islands had previously banned the sale of cigarettes, but it now permits sales from a government-run store. The Pacific island of Niue hopes to become the next country to prohibit the sale of tobacco as of 2008. Iceland is also proposing banning tobacco sales from shops, making it prescription-only and therefore dispensable only in pharmacies on doctor's orders. Singapore and the Australian state of Tasmania have proposed a 'tobacco free millennium generation initiative' by banning the sale of all tobacco products to anyone born in and after the year 2000. In March 2012, Brazil became the world's first country to ban all flavored tobacco including menthols. It also banned the majority of the estimated 600 additives used, permitting only eight. This regulation applies to domestic and imported cigarettes. Tobacco manufacturers had 18 months to remove noncompliant cigarettes, and 24 months to remove other forms of noncompliant tobacco. Under sharia law, the consumption of cigarettes by Muslims is prohibited.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.